On-demand webinar
Control Strategies for Therapeutic Oligonucleotides: Key Insights and Regulatory Expectations
Building robust, commercially ready control strategies for oligonucleotide therapeutics
Explore evolving regulatory expectations and practical recommendations for establishing control strategies that balance regulatory compliance with operational efficiency.
About this webinar
The oligonucleotide sector is growing rapidly, with antisense oligonucleotides (ASOs), siRNAs and guide RNAs for genome editing moving toward commercialization. At the same time, regulatory expectations continue to evolve, despite the lack of a dedicated official guideline for oligonucleotide therapeutics. Drawing on extensive experience as a CDMO in this field, this webinar highlights key regulatory insights and practical recommendations for establishing commercially ready control strategies.
What you’ll learn
- Key regulatory insights and expectations for therapeutic oligonucleotides.
- Practical strategies for establishing robust, commercially ready control strategies.
- How to balance regulatory compliance with operational efficiency.
Who is it for?
Teams involved in the development and commercialization of therapeutic oligonucleotides, particularly those working on control strategies and regulatory considerations.